Jump to Main Contents
国立がん研究センター 中央病院

Home > International Clinical Development

International Clinical Development

中村 健一写真

Kenichi Nakamura, M.D., Ph.D.

米盛 勧写真

Deputy Director
Kan Yonemori, M.D., Ph.D.

The Department of International Clinical Development (DICD) was established in November 2020 as one of the Specialist Centers of the National Cancer Center Hospital (NCCH). The mission of DICD is to contribute to improving the welfare of cancer patients in Japan, Asia, and the rest of the world by promoting the international initiatives in the area of research, education, and medical care at NCCH and forming a network of researchers worldwide.

In 2016, NCCH was designated as a promoting base of global clinical research by AMED and has expanded its international clinical research support function. In 2017, a Phase I study promotion project (ASIA ONE) was launched in the Asian region in collaboration with pharmaceutical companies, and NCCH has participated in many of the global Phase I studies as ASIA ONE.

Through the implementation of an Asian co-investigator-initiated clinical trial (PATHWAY) for breast cancer, we have worked on the establishment of academia-led network for drug development in the Asian region.

In addition, NCCH has actively expanded the range of international activities, including international joint research with JCOG and EORTC and the active acceptance of trainees and patients from overseas. While these activities have been undertaken autonomously by various departments, we will further develop them under a unified vision as NCCH on the occasion of the establishment of the Department of International Clical Development.

In September 2020, with support from the Japanese government and AMED, the Asian Clinical Trials Network for Cancers (ATLAS) Project was launched. The ATLAS project aims to create a universal health coverage in Asia by building a permanent network for early-phase cancer drug development through the development of clinical research infrastructure and educational and training activities in Asian countries. We believe we will be able to make a significant contribution to cancer patients in Japan, Asia, and the world thourgh the activities of our Department including the ATLAS project.

In order to maximize these contributions, it is essential to maintain close ties not only with medical institutions in Japan and overseas, but also with the Japanese government, PMDA, AMED, pharmaceutical companies, patient organizations, and many other parties.

We sincerely appreciate your kind support and guidance.

 Our Mission

We collaborate with people around the world in the fields of research, education, and practice. We will expand our activities internationally to contribute to the improvement of the welfare of cancer patients.

Our Vision

To collaborate with Asian countries to conduct global clinical trials in a speedy manner with high cost performance.
Deploy advanced medical technologies, including cancer genomic treatment, to Asian and other countries.
Strengthen the international medical care function to provide excellent cancer treatment in Japan to patients around the world.
To form a strong network of researchers and research supporters through various educational programs.
Play a central role in the international deployment of Japan-originated medical technologies in cooperation with the government, regulatory authorities, pharmaceutical companies, and patient groups.